This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Five Dumbest Things on Wall Street: Feb. 29

2. Jarvik's Artificial Rower

Pfizer (PFE - Get Report), we've missed you. Drug companies tend to provide plenty of dumbness, and Pfizer has been a stalwart, but had gone missing of late.

They're back. So where to start with this tale of free-form idiocy that took the form of now dearly departed commercials about a pill? The company set out to impress potential statin users by employing Dr. Robert Jarvik, the artificial heart pioneer, as their commercial spokesman and got accused of speaking falsely, but that wasn't the dumb part.

No, this huge drug company was forced to pull its big commercial campaign on Lipitor, the big cholesterol drug, because it was thought to be misleading in featuring Jarvik rowing a boat. Apparently, to make its shill look vibrant, Pfizer had to use a stunt double. You know how these nerdy medical sorts can be.

Dr. Jarvik supposedly cannot row an oar and chew gum at the same time. And, oh, by the way, he is also not technically a doctor -- at least one certified to practice --so making it seem like he is giving medical advice got a bit of a hairy eyeball from regulators, the fusspots. What could be next, filling out prescriptions with your Series 7? Puh-leez.

And now for the dumb part.

Pfizer sought to peddle a drug that is supposed to reduce the presence of an unseen substance so you can live a normal life ... with a guy most associated in the public consciousness still with a Dr. Seuss machine to substitute for the heart that kept Barney Clarke, a retired dentist, alive for a few extra, chained months.

Even someone not well versed in the field of advertising can conjure up better associations than this. But here is the association we are left with, after the intervention of Washington. The House Energy and Commerce Committee has, it was reported this week, asked the (count 'em) 10 advertising firms who worked on this stellar campaign to give up documents. About what, you ask? The use of body doubles.

Dumb-o-meter score: 88. Dr. Jarvik, you were getting paid over $1 million to peddle this drug. That would have covered a few rowing lessons, dude. Now, with a war still waging, Washington has to take their precious time from investigated Roger Clemens abscessed buttock cheek. Shame on you, sir.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
C $51.64 1.25%
MSFT $40.96 -0.02%
PFE $35.00 1.36%
TOL $39.21 -0.03%
YHOO $44.95 -0.33%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs